Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NVIDIA

These companies are leaders in their respective industries, and their stocks can be pillars for your portfolio.

2 Unstoppable Growth Stocks You Can Buy and Forget About

Apple

Costco

NextEra Energy

Southern Company

Tesla

UnitedHealth Group

I'm on the hunt for blue-chip stocks to buy for safety in this volatile market. The problem is the definition of what makes a company blue chip varies.

7 Blue-Chip Stocks to Buy for Safety in This Volatile Market

Becton, Dickinson and Co.

Becton Dickinson & Co. Deposit Repr 1/20th Cum Conv Pfd Registered Series A

There is more to the comparison, and in the sections below, we discuss why we believe BDX stock will offer better returns than LLY stock in the next three years.

This Healthcare Company Is Likely To Offer Better Returns Over Eli Lilly Stock

AstraZeneca

Roche Holding AG

Shares in pharmaceutical giants including Roche, Novo Nordisk, Eli Lilly and AstraZeneca were little changed Wednesday despite getting a ratings boost from analysts at Berenberg, who cited respective returns on research and development investment and the ability of those companies to withstand pressure coming from recent U.S drug price reform.

AstraZeneca, Eli Lilly and Roche among pharmaceutical companies upgraded for high returns on R&D investments, analysts say

Eli Lilly and Company (NYSE:LLY ) Morgan Stanley 20th Annual Global Healthcare Conference September 13, 2022 11:10 AM ET Company Participants Anat Ashkenazi - Senior Vice President and Chief Financial Officer Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Great. Well, thanks, everybody, for joining us.

Eli Lilly and Company (LLY) Presents at Morgan Stanley 20th Annual Global Healthcare Conference (Transcript)

Amazon

Biohaven Pharmaceutical Hld

Salesforce

Dollar General

Alphabet

Healthcare Realty Trust Inc

Microsoft

Neurocrine Biosciences

PayPal

Seagen

Snowflake

T-Mobile US

Big investors are famous for breaking rank from the S&P 500 crowd. So when you see a few agreeing on a stock, it's worth paying attention.

15 Stocks Billionaire Investors Agree It's Smart To Buy Now

Nasdaq

Exxon Mobil

See how to gauge demand and strength in Apple, Nasdaq and other stocks on the latest list of new buys by the best mutual funds. The post Top Funds Bet Over $1 Billion On Five Stocks, Including Apple appeared first on Investor's Business Daily.

Top Funds Bet Over $1 Billion On Five Stocks, Including Apple

New, late-breaking data show lebrikizumab responders reported long-lasting results at one year of treatment across measures of improvement in skin clearance, itch and disease extent and severity Results suggest less frequent, every four week dosing of lebrikizumab provided similar improvements to every two week dosing Regulatory submissions for U.S. and EU planned for this year INDIANAPOLIS , Sept. 8, 2022 /PRNewswire/ -- New detailed results from Eli Lilly and Company's (NYSE: LLY) Phase 3 monotherapy studies in atopic dermatitis (AD) showed investigational lebrikizumab provided robust and durable improvements in skin clearance and itch for patients who achieved a clinical response* at Week 16 through one year of treatment.

Lebrikizumab Dosed Every Four Weeks Maintained Durable Skin Clearance in Lilly's Phase 3 Monotherapy Atopic Dermatitis Trials

Eli Lilly and Company (NYSE:LLY ) Citigroup 17th Annual BioPharma Conference Call September 7, 2022 3:30 PM ET Company Participants Dan Skovronsky - Chief Scientific Officer, Chief Medical Officer & President of R&D Conference Call Participants Andrew Baum - Citigroup Andrew Baum So, good afternoon. Welcome back.

Eli Lilly and Company (LLY) Citigroup 17th Annual BioPharma Conference (Transcript)

INDIANAPOLIS , Sept. 7, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Verzenio® (abemaciclib) and Retevmo® (selpercatinib) will be presented at the 2022 European Society for Medical Oncology (ESMO) Congress, to be held September 9-13, 2022.

Lilly Announces Details of Presentations at ESMO Congress 2022

Novo Nordisk

Given that less than 3% of the 110 million obese Americans are being treated with drugs, new medications from Novo Nordisk AS ( NVO , Financial) and Eli Lilly and Co. ( LLY , Financial) could fatten the bottom line of both companies along with their share prices.

Novo Nordisk, Eli Lilly Could Fatten Up on Weight-Loss Treatments

INDIANAPOLIS , Aug. 31, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, Sept. 13, 2022. Anat Ashkenazi, Lilly's senior vice president and chief financial officer, will participate in a fireside chat at 11:10 a.m.

Lilly to Participate in Morgan Stanley 20th Annual Global Healthcare Conference

Baker Hughes Co

Chubb

Liberty Media Corp-Liberty Formula One

Netflix

Visa

Valero Energy

If you think the stock market pullback presents a buying opportunity, you may want to think again.

This outperforming fund manager looks for four traits in stocks — and has found them in these nine companies

AbbVie

Amgen

Bristol-Myers

CVS Health

Gilead Sciences

Merck

Pfizer

The stock market rally ran into the harsh reality last Friday that any interest rate pivot by the Federal Reserve may not come until 2024.

8 Safe ‘Strong Buy' Health Care Dividend Stocks to Buy as Summer Bear Market Rally Ends

Lilly (LLY) expects to launch five new medicines by 2023-end including Mounjaro for type II diabetes (already launched) and donanemab for early Alzheimer's disease.

Eli Lilly (LLY) Stock Up More Than 15% YTD: What Lies Ahead?

INDIANAPOLIS , Aug. 25, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend Citi's 17th Annual BioPharma Conference on Wednesday, Sept. 7, 2022. Daniel Skovronsky, M.D.

Lilly to Participate in Citi's 17th Annual BioPharma Conference

Should you steer clear of this pharma giant?

1 Green Flag and 1 Red Flag for Eli Lilly

The company sees good market signals from its recently launched potential blockbuster drug.

How Eli Lilly Is Thinning Out the Competition

Lilly (LLY) expects to launch five new medicines by 2023 end including Mounjaro for type II diabetes (already launched) and donanemab for early Alzheimer's disease.

Eli Lilly's (LLY) Potential New Products Key to Growth

Adobe

Johnson & Johnson

Ken Fisher (Trades, Portfolio), CEO and chief investment officer of Fisher Investments, disclosed in a regulatory filing that his firm's top five trades during the second quarter included boosts to its holdings in Johnson & Johnson ( JNJ , Financial), Apple Inc. ( AAPL , Financial) and Microsoft ( MSFT , Financial) and reductions to its positions in Eli Lily & Co. ( LLY , Financial) and Adobe Inc. ( ADBE , Financial).

Ken Fisher's Top 5 Trades in the 2nd Quarter

These stocks have been great options for both dividend and growth-oriented investors.

2 Dividend Stocks That Are Defying the Bear Market

- Stephen Fry to retire at the end of 2022 - Eric Dozier named Senior Vice President, Human Resources and Diversity - Winselow Tucker to join Lilly as Senior Vice President and Chief Commercial Officer for Loxo@Lilly INDIANAPOLIS , Aug. 11, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the upcoming retirement of one executive committee member, the naming of his successor, and the hiring of a new chief commercial officer for Loxo@Lilly. After more than 35 years at Lilly, Stephen Fry, senior vice president, human resources and diversity, will retire at the end of 2022.

Lilly Announces Leadership Transition in Human Resources and New Chief Commercial Officer for Loxo@Lilly

Hit by a spate of bad news, Eli Lilly and Co. ( LLY , Financial) has lost nearly 8% of its market value since July 28. Is it time for investors to join those bailing on the stock or jump in on the dip?

News for Eli Lilly Stock (LLY)